Sanofi introduces new drug for hypertension
Sanofi has reinforced its sustained commitment to healthcare through the provision of affordable medicines that are tailored to the needs of patients with the introduction of APROVASC, a fixed-dose combination treatment for the management of hypertension.
Sanofi at the launch of the product, last week, in Lagos, said the introduction of new APROVASC range, and the continual support of establishing clinics for the better management of the disease, is in direct response to the healthcare needs of patients with hypertension in Nigeria.
Also, to better support the patients in the management of their disease, Sanofi continues with its access to healthcare ambition in the opening of diabetes and hypertension clinics in partnership with health authorities.
The first clinic was inaugurated at the Lagos State University Teaching Hospital (LASUTH) on January 29, 2015. Several studies have shown that, in Nigeria, about 28.9 per cent of the population has raised blood pressure while about 82 per cent are not aware of this disease condition.
It has been reported that by 2030, up to 39.1 million people aged at least 20 years may live with hypertension if nothing is done to reverse the trend.
People with uncontrolled hypertension are exposed to many complications including stroke, heart attack, kidney failure and problems with vision, which can be controlled by adopting healthy diets, lifestyle changes and, in many cases, treatment with medications.
General Manager, Sanofi Nigeria-Ghana, Abderrahmane Chakibi, said: “By introducing a new antihypertensive treatment, Sanofi demonstrates its commitment to patients through improving access to high quality solutions in the field of hypertension management in Nigeria.
APROVASC introduction is another example of Sanofi’s engagement to always provide advanced and innovative treatments in response to patients’ specific needs with the highest efficacy and comfort. This unique combination is the result of years of development, clinical studies and safety proofing.
“Delivering innovative treatments and a full portfolio adapted to the needs of patients locally is at the core of what we, at Sanofi, have done for nearly a century.
But medications alone are not enough. For many years, we have been supporting healthcare professionals in their daily practice through training and other tailored services.
Through leveraging APROVASC availability in Nigeria, Sanofi will continue to contribute to making the lives of Nigerian hypertensive patients healthier.”
Hypertension, also known as high blood pressure or arterial hypertension is a chronic medical condition in which the blood pressure in the arteries is elevated.
Hypertension is usually described as a ‘silent killer’ because it usually does not cause symptoms initially, but sustained hypertension over time is a major risk factor for conditions such as heart attack, heart failure, loss of vision and kidney failure. Dietary and lifestyle changes can improve blood pressure control and decrease the risk of health complications.
Treatment with medication is still often necessary in people for whom lifestyle changes are not enough or not effective. Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs.
Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
No comments yet